When comparing the clinical parameters, the newly diagnosed DMARD naïve RA patients had significantly higher CRP, ESR, and DAS28 scores than the MTX treated patients (P ≤ 0.01). The gene discussed is CRP; the disease is rheumatoid arthritis.